 Seres Therapeutics was founded in 2010 at a time when the Human Microbiome Project was hot. So Seres was there when microbiomics began to get serious. Nestle Health Science has been an early investor and concluded a major deal on marketing rights in early 2016. The first product, SER-109, is being readied for market. 